Search
forLearn 1 of 2
All learn results →Community 10 of 393
- What I’ve learned From 8 Months on Pyrilutamide
- Consenus on Kx-826/pyrilutamide vs ru58841
- Anyone having success with pyrilutamide?
- So why did the first pyrilutamide phase III fail?
- Is RU58841 safe or is pyrilutamide better option
- 2 months on topical finasteride + minoxidil + pyrilutamide
- Six month results of pyrilutamide and Alfatrodial
- My thoughts on Pyrilutamide after 6 months
- Why are there no meaningful baseline blood tests for pyrilutamide (KX-826) like there are for finasteride?
- Pyrilutamide and Topical Fin/Min
Research 10 of 33
- 587 Efficacy and Safety of topical KX-826 in Male Subjects with Androgenetic Alopecia:A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study
- Development and Validation of Androgen-induced Hair Loss and Anagen Induction Mouse Models for Pharmacological Evaluation of Anti-Androgenic Agents
- The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithms
- Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
- Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
- Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
- Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
- Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
- Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
- Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia